Insperity (NSP) opened 2026 with Q1 revenue of US$1.9b and basic EPS of US$0.88, alongside net income of US$33m. On a trailing twelve month basis, revenue stands at US$6.8b and basic EPS at a loss of US$0.66 tied to a net loss of US$25m. Over recent quarters the company has reported revenue between US$1.6b and US$1.9b, with quarterly basic EPS ranging from a profit of US$1.34 to a loss of US$0.88. This places the latest figures against a backdrop of shifting margins and profitability pressure. Taken together, these results indicate that revenue is holding at a large scale while margins remain tight, keeping investor attention on how efficiently that topline is being converted into earnings.

See our full analysis for Insperity.

With the headline numbers in place, the next step is to see how this earnings report aligns with widely followed views on Insperity's growth potential, risk profile, and path back to consistent profitability.

LTM swings from US$91m profit to US$25m loss

• On a trailing twelve month basis, Insperity moved from net income of US$91 million and basic EPS of US$2.39 in Q4 2024 to a net loss of US$25 million and basic EPS of US$0.66 loss by Q1 2026, even though revenue over that window rose from US$6.6b to US$6.8b.
• Consensus narrative expects profit margins to lift from roughly breakeven today to 1.2% in three years and earnings to reach US$94.5 million. However, the recent shift from US$91 million profit to a US$25 million loss highlights how benefits costs and SMB exposure can still disrupt that path, even with revenue holding around US$6.8b.
  • Supporters of the consensus view point to pricing changes, benefit plan adjustments and the UnitedHealthcare contract as tools to rebuild margin, but the current loss shows those levers are not yet fully reflected in reported earnings.
  • The fact that trailing revenue has grown from US$6.6b to US$6.8b while profitability flipped to a loss is exactly the kind of margin tension that both bullish and cautious narratives focus on when they talk about healthcare cost trends and operating leverage.

Quarterly EPS whipsaws between US$1.34 and a US$0.88 loss

• Over the last five reported quarters, basic EPS has ranged from a profit of US$1.34 in Q1 2025 to a loss of US$0.88 in Q4 2025, before returning to a profit of US$0.88 in Q1 2026, while quarterly revenue stayed in a relatively tight band around US$1.6b to US$1.9b.
• Bears argue that this kind of earnings volatility, together with the company being unprofitable over the last year and losses widening by about 21.8% per year over five years, shows that margin pressure from healthcare costs and SMB exposure may persist even if revenue trends look steady.
  • The swing from a US$33 million loss in Q4 2025 to US$33 million profit in Q1 2026, without a major shift in revenue, lines up with bearish concerns that benefits cost trends and insurance contract dynamics can cause sharp quarter to quarter EPS moves.
  • At the same time, the path from a US$91 million trailing profit in late 2024 to a US$25 million trailing loss in early 2026 supports the cautious view that earnings normalization is not yet evident in the reported numbers, despite various forecasts calling for a return to profitability within three years.

Over the last few quarters, this pattern of EPS whipsaws around a relatively stable topline is exactly what skeptics highlight when they question how smooth any recovery in margins is likely to be. 🐻 Insperity Bear Case

Low P/S of 0.2x versus DCF fair value of US$158.11

• At a current share price of US$28.53, the stock trades on a P/S of about 0.2x compared with an industry level of 1.2x and peer average of 0.7x, while the provided DCF fair value of US$158.11 and a single allowed analyst price target of US$39.50 both sit far above that spot price.
• Supporters of the bullish view see this wide gap between market price and both DCF fair value and the analyst target as an opportunity, especially with forecasts calling for earnings to turn positive and grow at about 82.7% per year. However, the current trailing loss of US$25 million and weak coverage of the 8.41% dividend show that much of the bullish case still depends on future margin repair rather than current cash generation.
  • The contrast between a low 0.2x P/S on roughly US$6.8b of trailing revenue and the DCF fair value of US$158.11 heavily supports the idea that expectations in the price are conservative compared with the growth and margin profile implied in the forecasts.
  • On the other hand, the dividend not being covered by earnings or free cash flow, alongside recent share price volatility, is consistent with the market assigning a discount while it waits for the forecast improvement in profitability to show up in reported figures.

If you want to see how optimistic investors connect these valuation gaps to the earnings story, check out the latest bull case on Insperity 🐂 Insperity Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Insperity on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After all this, does the mix of pressure and potential make you cautious or curious? Move quickly, review the figures for yourself, and weigh the 3 key rewards and 2 important warning signs

See What Else Is Out There

Insperity's recent swing from a US$91m profit to a US$25m loss, along with whipsawing EPS and an uncovered dividend, underlines meaningful earnings and income risk.

If this kind of volatility makes you want steadier candidates, take a few minutes today to scan the 67 resilient stocks with low risk scores and focus on companies with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.